NASDAQ: LYELLyell Immunopharma Inc Stock Ownership - Who owns Lyell Immunopharma?
Insider buying vs selling
Have Lyell Immunopharma Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Jarrad Mattieu Aguirre | Med | 2026-10-12 | 422 | $8.63 | $3.64kSell |
| David Shook | Med | 2026-09-10 | 500 | $12.70 | $6.35kSell |
| Gary K. Lee | CSci | 2026-08-21 | 1,457 | $15.54 | $22.64kSell |
| Stephen J. Hill | COO | 2026-08-21 | 989 | $15.54 | $15.37kSell |
| Lynn Seely | CEO;Pres | 2026-08-21 | 9,589 | $15.54 | $149.01kSell |
| Lynn Seely | CEO;Pres | 2026-08-10 | 390 | $14.34 | $5.59kSell |
| Stephen J. Hill | COO | 2026-08-10 | 89 | $14.34 | $1.28kSell |
| Gary K. Lee | CSci | 2026-08-10 | 131 | $14.34 | $1.88kSell |
| Veronica Sanchez Bulis | Ctrl;VP | 2026-08-10 | 621 | $14.34 | $8.91kSell |
| Innovative Cellular Therapeutics Holdings Ltd | 10% Owner | 2026-07-17 | 10 | $13.70 | $137.00Sell |
LYEL insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when LYEL insiders and whales buy or sell their stock.
LYEL Shareholders
What type of owners hold Lyell Immunopharma Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Robert Nelsen | 222.89% | 54,619,074 | $588.25M | Insider |
| Arch Venture Partners IX LLC | 159.74% | 39,143,667 | $421.58M | Insider |
| Glaxosmithkline PLC | 123.46% | 30,253,189 | $325.83M | Insider |
| Richard Klausner | 23.02% | 5,641,764 | $60.76M | Insider |
| Hans Edgar Bishop | 19.12% | 4,685,614 | $50.46M | Insider |
| Innovative Cellular Therapeutics Holdings Ltd | 11.66% | 2,857,480 | $30.78M | Insider |
| Cellular Therapeuti Innovative | 11.66% | 2,857,480 | $30.78M | Insider |
| Cellular Therapeutics Holding Innovative | 11.32% | 2,774,980 | $29.89M | Insider |
| Arch Venture Fund XIII LP | 7.54% | 1,848,755 | $19.91M | Insider |
| Cathy Friedman | 1.03% | 253,188 | $2.73M | Insider |
LYEL vs Biotech Stocks
Lyell Immunopharma Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.